Advances in the development of hybrid anticancer drugs

Expert Opinion on Drug Discovery

Volumn 8, Issue 8, 2013, Pages 1029-1047

  Fortin, Sébastien ^a   Bérubé, Gervais ^a  

^a UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

Author keywords

Anticancer agents; Combi molecules; Drug design; Drug targeting; Hybrids

Indexed keywords

5,11 DIKETOINDENOISOQUINOLINE; ACRONINE; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; BEXAROTENE; CAMPTOTHECIN; CHALCONE; CHLORAMBUCIL; CHLORMETHINE; COUMARIN; DASATINIB; DAUNORUBICIN; DICTYOSTATIN; DISCODERMOLIDE; DOXORUBICIN; ENTINOSTAT; FLUOROURACIL; IMATINIB; INDOLO[2,3 B]QUINOLINE; MELPHALAN; NEO TANSHINLACTONE; NILOTINIB; PROPAFENONE; PSOROSPERMIN; QUINOLINE; RESVERATROL; TRIAZINE; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANTIPROLIFERATIVE ACTIVITY; CELL CYCLE PROGRESSION; DNA ALKYLATION; DNA STRAND BREAKAGE; DRUG MECHANISM; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; HYBRID; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; NEOPLASMS;

EID: 84880729529     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.798296     Document Type: Review

References (69)

1. Gediya LK, Njar VC. Promise and challenges in drug discovery and development of hybrid anticancer drugs. Expert Opin Drug Discov 2009;4(11):1099-111
2. Viegas-Junior C, Danuello A, da Silva Bolzani V, et al. Molecular hybridization: A useful tool in the design of new drug prototypes. Curr Med Chem 2007;14(17):1829-52
3. Fox BM, Xiao X, Antony S, et al. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids. J Med Chem 2003;46(15):3275-82
4. Nguyen HT, Lallemand MC, Boutefnouchet S, et al. Antitumor psoropermum xanthones and sarcomelicope acridones: Privileged structures implied in DNA alkylation. J Nat Prod 2009;72(3):527-39
5. Wang D, Zhang Z, Lu X, et al. Hybrid compounds as new Bcr/Abl inhibitors. Bioorg Med Chem Lett 2011;21(7):1965-8
6. Lee KW, Kim JH, Park JH, et al. Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells. Anticancer Res 2006;26(5 A):3429-38
7. Florence GJ, Gardner NM, Paterson I. Development of practical syntheses of the marine anticancer agents discodermolide and dictyostatin. Nat Prod Rep 2008;25(2):342-75
8. Paterson I, Naylor GJ, Fujita T, et al. Total synthesis of a library of designed hybrids of the microtubule-stabilising anticancer agents taxol, discodermolide and dictyostatin. Chem Commun 2010;46(2):261-3
9. Paterson I, Naylor GJ, Wright AE. Total synthesis of a potent hybrid of the anticancer natural products dictyostatin and discodermolide. Chem Commun 2008(38):4628-30
10. Meunier B. Hybrid molecules with a dual mode of action: Dream or reality? Acc Chem Res 2008;41(1):69-77
11. Singh P, Paul K. Studies of interactions between uracil-based hybrid molecules and P-glycoprotein-search for multidrug resistance modulators. Bioorg Med Chem 2006;14(21):7183-6
12. Belluti F, Fontana G, Bo LD, et al. Design, synthesis and anticancer activities of stilbene-coumarin hybrid compounds: Identification of novel proapoptotic agents. Bioorg Med Chem 2010;18(10):3543-50
13. Nordenberg J, Fenig E, Landau M, et al. Effects of psychotropic drugs on cell proliferation and differentiation. Biochem Pharmacol 1999;58(8):1229-36
14. Guandalini L, Cellai C, Laurenzana A, et al. Design, synthesis and preliminary biological evaluation of new hydroxamate histone deacetylase inhibitors as potential antileukemic agents. Bioorg Med Chem Lett 2008;18(18):5071-4
15. Tavera-Mendoza LE, Quach TD, Dabbas B, et al. Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist. Proc Natl Acad Sci USA 2008;105(24):8250-5
16. Lamblin M, Dabbas B, Spingarn R, et al. Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids. Bioorg Med Chem 2010;18(11):4119-37
17. Fischer J, Wang TT, Kaldre D, et al. Synthetically accessible non-secosteroidal hybrid molecules combining vitamin D receptor agonism and histone deacetylase inhibition. Chem Biol 2012;19(8):963-71
18. Mizuno CS, Paul S, Suh N, et al. Synthesis and biological evaluation of retinoid-chalcones as inhibitors of colon cancer cell growth. Bioorg Med Chem Lett 2010;20(24):7385-7
19. Sashidhara KV, Kumar A, Kumar M, et al. Synthesis and in vitro evaluation of novel coumarin-chalcone hybrids as potential anticancer agents. Bioorg Med Chem Lett 2010;20(24):7205-11
20. Bednarek E, Bocian W, Sitkowski J, et al. 1H and 13C NMR data for indolo [2,3-b]quinoline-aminoglycoside hybrids, a novel potent anticancer drug family. Magn Reson Chem 2006;44(4):459-62
21. Kumar R, Gupta L, Pal P, et al. Synthesis and cytotoxicity evaluation of (tetrahydro-beta-carboline)-1,3,5-triazine hybrids as anticancer agents. Eur J Med Chem 2010;45(6):2265-76
22. Kolesinska B, Barszcz K, Kaminski ZJ, et al. Synthesis and cytotoxicity studies of bifunctional hybrids of nitrogen mustards with potential enzymes inhibitors based on melamine framework. J Enzyme Inhib Med Chem 2012;27(5):619-27
23. Gerratana B. Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines. Med Res Rev 2012;32(2):254-93
24. Wang JJ, Shen YK, Hu WP, et al. Design, synthesis, and biological evaluation of pyrrolo[2,1-c][1,4] benzodiazepine and indole conjugates as anticancer agents. J Med Chem 2006;49(4):1442-9
25. Ismail MMF, Rateb HS, Hussein MMM. Synthesis and docking studies of novel benzopyran-2-ones with anticancer activity. Eur J Med Chem 2010;45(9):3950-9
26. Ahmed K, Matsuya Y, Nemoto H, et al. Mechanism of apoptosis induced by a newly synthesized derivative of macrosphelides with a thiazole side chain. Chem Biol Interact 2009;177(3):218-26
27. Matsuya Y, Kobayashi Y, Kawaguchi T, et al. Design, synthesis, and biological evaluation of artificial macrosphelides in the search for new apoptosis-inducing agents. Chem Eur J 2009;15(23):5799-813
28. Havrylyuk D, Kovach N, Zimenkovsky B, et al. Synthesis and anticancer activity of isatin-based pyrazolines and thiazolidines conjugates. Arch Pharm 2011;344(8):514-22
29. Kumar K, Sagar S, Esau L, et al. Synthesis of novel 1H-1,2,3-triazole tethered C-5 substituted uracil-isatin conjugates and their cytotoxic evaluation. Eur J Med Chem 2012;58:153-9
30. Singh P, Sharma P, Anand A, et al. Azide-alkyne cycloaddition en route to novel 1H-1,2,3-triazole tethered isatin conjugates with in vitro cytotoxic evaluation. Eur J Med Chem 2012;55:455-61
31. Kamal A, Bharathi EV, Reddy JS, et al. Synthesis and biological evaluation of 3,5-diaryl isoxazoline/isoxazole linked 2,3-dihydroquinazolinone hybrids as anticancer agents. Eur J Med Chem 2011;46(2):691-703
32. Xie L, Zhao Y, Zhai X, et al. The application of tandem aza-wittig reaction to synthesize artemisinin-guanidine hybrids and their anti-tumor activity. Arch Pharm 2011;344(10):631-8
33. Bastien D, Leblanc V, Asselin E, et al. First synthesis of separable isomeric testosterone dimers showing differential activities on prostate cancer cells. Bioorg Med Chem Lett 2010;20(7):2078-81
34. Domarkas J, Dudouit F, Williams C, et al. The combi-targeting concept: Synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J Med Chem 2006;49(12):3544-52
35. Golabi N, Brahimi F, Huang Y, et al. A bioanalytical investigation on the exquisitely strong in vitro potency of the EGFR-DNA targeting type II combi-molecule ZR2003 and its mitigated in vivo antitumour activity. J Pharm Biomed Anal 2011;56(3):592-9
36. Watt HL, Rachid Z, Jean-Claude BJ. The concept of divergent targeting through the activation and inhibition of receptors as a novel chemotherapeutic strategy: Signaling responses to strong DNA-reactive combinatorial mimicries. J Signal Transduct 2012;2012:282050
37. Fang Y, Qiu Q, Domarkas J, et al. "Combi-targeting" mitozolomide: Conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer. Prostate 2012;72(12):1273-85
38. Rachid Z, Brahimi F, Qiu Q, et al. Novel nitrogen mustard-armed combimolecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: Discovery of an unusual structure-activity relationship. J Med Chem 2007;50(11):2605-8
39. MacPhee M, Rachid Z, Todorova M, et al. Characterization of the potency of epidermal growth factor (EGFR)- DNA targeting combi-molecules containing a hydrolabile carbamate at the 3-position of the triazene chain. Invest New Drugs 2011;29(5):833-45
40. Golabi N, Rachid Z, Qiu Q, et al. In vitro and in vivo biodistribution of ZRS1, a stabilized type I N-acetoxymethyl carbamate-containing combi-molecule. Drug Metab Lett 2011;5(2):141-9
41. Huang Y, Rachid Z, Jean-Claude BJ. MGMT is a molecular determinant for potency of the DNA-EGFR-combimolecule ZRS1. Mol Cancer Res 2011;9(3):320-31
42. Rachid Z, Katsoulas A, Williams C, et al. Optimization of novel combimolecules: Identification of balanced and mixed bcr-abl/DNA targeting properties. Bioorg Med Chem Lett 2007;17(15):4248-53
43. Smyre CL, Saluta G, Kute TE, et al. Inhibition of DNA synthesis by a platinum-acridine hybrid agent leads to potent cell kill in nonsmall cell lung cancer. ACS Med Chem Lett 2011;2(11):870-4
44. Singh P, Raj R, Kumar V, et al. 1,2,3-Triazole tethered b-lactam-Chalcone bifunctional hybrids: Synthesis and anticancer evaluation. Eur J Med Chem 2012;47(1):594-600
45. Mourad MAE, Abdel-Aziz M, Abuo-Rahma GEDAA, et al. Design, synthesis and anticancer activity of nitric oxide donating/chalcone hybrids. Eur J Med Chem 2012;54:907-13
46. Kamal A, Ramesh G, Srinivas O, et al. Synthesis and antitumour activity of pyrene-linked pyrrolo [2,1-c][1,4] benzodiazepine hybrids. Bioorg Med Chem Lett 2004;14(2):471-4
47. Kamal A, Srinivas O, Ramulu P, et al. Synthesis of C8-linked pyrrolo[2,1-c] [1,4]benzodiazepine-acridone/acridine hybrids as potential DNA-binding agents. Bioorg Med Chem Lett 2004;14(15):4107-11
48. Dao KL, Hanson RN. Targeting the estrogen receptor using steroid-therapeutic drug conjugates (hybrids). Bioconjug Chem 2012;23(11):2139-58
49. Descôteaux C, Leblanc V, Bélanger G, et al. Improved synthesis of unique estradiol-linked platinum(II) complexes showing potent cytocidal activity and affinity for the estrogen receptor alpha and beta. Steroids 2008;73(11):1077-89
50. Van Themsche C, Parent S, Leblanc V, et al. VP-128, a novel oestradiolplatinum( II) hybrid with selective anti-tumour activity towards hormone-dependent breast cancer cells in vivo. Endocr Relat Cancer 2009;16(4):1185-95
51. Saha P, Descoteaux C, Brasseur K, et al. Synthesis, antiproliferative activity and estrogen receptor a affinity of novel estradiol-linked platinum(II) complex analogs to carboplatin and oxaliplatin. Potential vector complexes to target estrogen-dependent tissues. Eur J Med Chem 2012;48:385-90
52. Adsule S, Banerjee S, Ahmed F, et al. Hybrid anticancer agents: Isothiocyanate-progesterone conjugates as chemotherapeutic agents and insights into their cytotoxicities. Bioorg Med Chem Lett 2010;20(3):1247-51
53. Saha P, Fortin S, Leblanc V, et al. Design, synthesis, cytocidal activity and estrogen receptor a affinity of doxorubicin conjugates at 16a-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer. Steroids 2012;77(11):1113-22
54. Trafalis DTP, Camoutsis C, Papageorgiou A. Research on the anti-tumour effect of steroid lactam alkylator (NSC-294859) in comparison with conventional chemotherapeutics in malignant melanoma. Melanoma Res 2005;15:273-81
55. Descôteaux C, Brasseur K, Leblanc V, et al. Design of novel tyrosine-nitrogen mustard hybrid molecules active against uterine, ovarian and breast cancer cell lines. Steroids 2012;77(5):403-12
56. Miot-Noirault E, Reux B, Debiton E, et al. Preclinical investigation of tolerance and antitumour activity of new fluorodeoxyglucose-coupled chlorambucil alkylating agents. Invest New Drugs 2011;29(3):424-33
57. Peyrode C, Weber V, David E, et al. Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: In vitro and in vivo preclinical studies. Invest New Drugs 2012;30(4):1782-90
58. Brel V, Annereau JP, Vispe S, et al. Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II. Biochem Pharmacol 2011;82(12):1843-52
59. Barret JM, Kruczynski A, Vispe S, et al. F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system. Cancer Res 2008;68(23):9845-53
60. Kruczynski A, Vandenberghe I, Pillon A, et al. Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system. Invest New Drugs 2011;29(1):9-21
61. Kumamoto T, Suzuki K, Kim SK, et al. Synthesis, physical properties, and cytotoxicity of Nitroxyl-Aziridine hybrid. Helv Chim Acta 2010;93(11):2109-14
62. Chezal JM, Papon J, Labarre P, et al. Evaluation of radiolabeled (hetero) aromatic analogues of N-(2- diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma. J Med Chem 2008;51(11):3133-44
63. Desbois N, Gardette M, Papon J, et al. Design, synthesis and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemo-radionuclide therapy approach to melanoma. Bioorg Med Chem 2008;16(16):7671-90
64. Gardette M, Papon J, Bonnet M, et al. Evaluation of new iodinated acridine derivatives for targeted radionuclide therapy of melanoma using 125I, an Auger electron emitter. Invest New Drugs 2011;29(6):1253-63
65. Banerjee R, Huang Y, Qiu Q, et al. The combi-targeting concept: Mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle. Cell Signal 2011;23(4):630-40
66. Khan H, Badshah A, Murtaz G, et al. Synthesis, characterization and anticancer studies of mixed ligand dithiocarbamate palladium(II) complexes. Eur J Med Chem 2011;46(9):4071-7
67. Al-Safadi S, Domarkas J, Han Y, et al. Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting combi-molecule ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach. Anticancer Drugs 2012;23(5):483-93
68. Larroque-Lombard AL, Ning N, Rao S, et al. Biological effects of AL622, a molecule rationally designed to release an EGFR and a c-Src kinase inhibitor. Chem Biol Drug Des 2012;80(6):981-91
69. Keller TH, Pichota A, Yin Z. A practical view of druggability. Curr Opin Chem Biol 2006;10:357-61